Investor Presentaiton slide image

Investor Presentaiton

31st January 2024 Our Institution business is of Anti-Malaria in Africa 244 FY20 Revenue (INR Cr) 271 (8%) CAGR 206 190 FY21 FY22 FY23 1st Generic company to obtain WHO Pre-Qualification Stagnates Due to lower procurement by aid agencies 1 Billion+ Patients treated till date 21 ajanta
View entire presentation